NO20020311L - 1,4,5,6-tetrahydropyrimidinderivat som en vitronektininhibitor - Google Patents

1,4,5,6-tetrahydropyrimidinderivat som en vitronektininhibitor

Info

Publication number
NO20020311L
NO20020311L NO20020311A NO20020311A NO20020311L NO 20020311 L NO20020311 L NO 20020311L NO 20020311 A NO20020311 A NO 20020311A NO 20020311 A NO20020311 A NO 20020311A NO 20020311 L NO20020311 L NO 20020311L
Authority
NO
Norway
Prior art keywords
ethyl
formula
tetrahydropyrimidin
ylcarbamoyl
sulfonylamino
Prior art date
Application number
NO20020311A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020311D0 (no
Inventor
Gerhard Breipohl
Anuschirwan Peyman
Theodor Wollmann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20020311D0 publication Critical patent/NO20020311D0/no
Publication of NO20020311L publication Critical patent/NO20020311L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20020311A 1999-07-21 2002-01-21 1,4,5,6-tetrahydropyrimidinderivat som en vitronektininhibitor NO20020311L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114372A EP1070707A1 (en) 1999-07-21 1999-07-21 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
PCT/EP2000/006504 WO2001007417A1 (en) 1999-07-21 2000-07-08 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor

Publications (2)

Publication Number Publication Date
NO20020311D0 NO20020311D0 (no) 2002-01-21
NO20020311L true NO20020311L (no) 2002-01-21

Family

ID=8238643

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020311A NO20020311L (no) 1999-07-21 2002-01-21 1,4,5,6-tetrahydropyrimidinderivat som en vitronektininhibitor

Country Status (29)

Country Link
US (1) US6900318B1 (cs)
EP (2) EP1070707A1 (cs)
JP (1) JP2003505450A (cs)
KR (1) KR20020063838A (cs)
CN (1) CN1361767A (cs)
AR (1) AR024794A1 (cs)
AT (1) ATE286030T1 (cs)
AU (1) AU775567B2 (cs)
BG (1) BG106322A (cs)
BR (1) BR0012554A (cs)
CA (1) CA2379086C (cs)
CZ (1) CZ200285A3 (cs)
DE (1) DE60017150D1 (cs)
EA (1) EA200200187A1 (cs)
EE (1) EE200200031A (cs)
HK (1) HK1048316A1 (cs)
HR (1) HRP20020057A2 (cs)
HU (1) HUP0201939A3 (cs)
IL (1) IL147396A0 (cs)
MX (1) MXPA02000674A (cs)
MY (1) MY133525A (cs)
NO (1) NO20020311L (cs)
NZ (1) NZ516233A (cs)
PL (1) PL353014A1 (cs)
SK (1) SK522002A3 (cs)
TR (1) TR200200116T2 (cs)
WO (1) WO2001007417A1 (cs)
YU (1) YU90201A (cs)
ZA (1) ZA200110361B (cs)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
US6313119B1 (en) * 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
YU47200A (sh) * 1998-01-23 2002-11-15 Aventis Pharma Deutschland Gmbh. Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije

Also Published As

Publication number Publication date
KR20020063838A (ko) 2002-08-05
BG106322A (en) 2002-08-30
IL147396A0 (en) 2002-08-14
BR0012554A (pt) 2002-04-16
MXPA02000674A (es) 2002-07-30
US6900318B1 (en) 2005-05-31
EP1204646B1 (en) 2004-12-29
CA2379086A1 (en) 2001-02-01
HUP0201939A2 (hu) 2002-12-28
NO20020311D0 (no) 2002-01-21
AR024794A1 (es) 2002-10-23
YU90201A (sh) 2004-07-15
DE60017150D1 (de) 2005-02-03
HRP20020057A2 (en) 2003-06-30
JP2003505450A (ja) 2003-02-12
AU775567B2 (en) 2004-08-05
CN1361767A (zh) 2002-07-31
ZA200110361B (en) 2002-12-18
HK1048316A1 (zh) 2003-03-28
PL353014A1 (en) 2003-10-06
EE200200031A (et) 2003-02-17
MY133525A (en) 2007-11-30
EP1070707A1 (en) 2001-01-24
EP1204646A1 (en) 2002-05-15
SK522002A3 (en) 2003-05-02
AU6822600A (en) 2001-02-13
WO2001007417A1 (en) 2001-02-01
CZ200285A3 (cs) 2003-02-12
EA200200187A1 (ru) 2002-10-31
NZ516233A (en) 2004-07-30
CA2379086C (en) 2009-01-06
ATE286030T1 (de) 2005-01-15
TR200200116T2 (tr) 2002-04-22
HUP0201939A3 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
EP0686625B1 (en) Anthranilic acid derivative
JP4359817B2 (ja) ｐ３８阻害剤としての窒素ヘテロ原子含有ヘテロアリール尿素
MX2021007251A (es) Formas polimorficas novedosas de un inhibidor de tgf?.
Das et al. Design and synthesis of 1, 2, 3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors
MY148643A (en) Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
FI112483B (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-[2-[4-(6-fluori-1,2-bentsisoksatsol-3-yyli) -1-piperidinyyli]etyyli]-2-alkyyli-pyrimidin-4-onijohdannaisten valmistamiseksi
HUT73813A (en) Anti-athero-sclerotic diaryl compounds, process to prepare them and pharmaceutical compositions contg. them
ATE411288T1 (de) Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
AU2008235212A1 (en) Inhibitors of histone deacetylase
YU71102A (sh) Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje
CL2004001074A1 (es) COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA,
JPH06184096A (ja) ヘテロ芳香族化合物およびこれを含有する植物保護剤
Z. Laczkowski et al. Synthesis, in vitro biological screening and molecular docking studies of novel camphor-based thiazoles
Michaelides et al. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors
JP2005514455A (ja) 芳香族チオエーテル肝臓ｘ受容体モジュレータ
JPH06211748A (ja) 置換アクリル酸エステルおよびこれを含有する殺菌剤
NO20020311L (no) 1,4,5,6-tetrahydropyrimidinderivat som en vitronektininhibitor
EP2045246A1 (en) Derivatives of benzo[d] isothiazoles as histone deacetylase inhibitors
JP6484168B2 (ja) 抗ウイルス活性を有するメタンチオン化合物
NO173057B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzanilidderivater
JPH07501325A (ja) 置換ピリジン−４−カルボキサミド類
MX2024005933A (es) Moduladores de htt pata tratar la enfermedad de huntington.
TW200635911A (en) Sulfanyl substituted phenyl methanones
CN113660932B (zh) 具有侧链烷基与烯基延伸的苯基衍生物及包括有其的药学组合物
JP2012036124A (ja) Ｈｉｖ複製阻害剤

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application